MALVERN, Pa., June 10, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) recently granted Siemens Healthcare (NYSE: SI) 510(k) clearance for the Biograph mMR, the first system worldwide to enable simultaneous whole-body acquisition of data from magnetic resonance (MR) and positron emission tomography (PET).
While MR provides exquisite morphological and functional details in soft tissue, PET goes further to investigate the human body at the level of cellular activity and metabolism. The Biograph mMR enables users to generate the location, function, and metabolic activity of organs in a single image at the same time. Designed to provide a more complete diagnostic picture, this 3T hybrid system illustrates Siemens' vision: to deliver technologies that enable physicians to determine effective diagnosis, better outcomes, and more efficient treatment.
The Biograph mMR allows a combined approach to imaging anatomical, functional and biochemical characteristics of disease. Potential clinical applications for molecular MR include the early identification and staging of malignancies, therapy planning, and treatment. The Biograph mMR shows the greatest promise in oncologic and neurologic applications where MR and PET have proven their clinical value.
"Integrating these two powerful modalities into one simultaneous whole-body system represents a breakthrough innovation. More powerful diagnostic tools can bring greater efficiency to healthcare and can help to improve human health," said Gregory Sorensen, MD, chief executive officer, Siemens Healthcare USA and Canada. "Together with our customers, we are striving to improve care for all patients in a sustainable and cost-effective manner."
The Biograph mMR has been adopted as a diagnostic imaging research tool for developing novel approaches to the understanding, diagnosis, and treatment of disease. Initial Biograph mMR installations are at the University Hospital in Tuebingen and the University Hospital "Klinikum rechts der Isar" of the Munich Technical University, both in Germany; and Boston's Massachusetts General Hospital.
"We've initiated clinical use testing of Biograph mMR in an effort to diagnose diseases at a very early stage; to see the progression of disease and to use that information to develop a therapy plan precisely focused on the respective patient. Furthermore, we plan to use the system for cancer follow-up in the long run, by reducing radiation exposure by the use of the system," says Prof. Dr. Markus Schwaiger, director of the Clinic for Nuclear Medicine at the "Klinikum rechts der Isar" of the Munich Technical University.
Prior to the Biograph mMR, the integration of MR and PET technologies was nearly impossible. The conventional PET detectors, which use photomultiplier tubes, could not be used in the strong magnetic field generated by an MR system. Integration was further limited by the lack of space inside the MR device. For this reason, previous MR-PET fusion imaging solutions relied not on simultaneous imaging but rather sequential imaging (or post-scan registration) of MR and PET data, resulting in a significant time lag.
The Biograph mMR represents the first complete integration of diagnostic-grade MR and PET into a single-gantry whole-body scanner through incorporation of its 3T MR technology and unique Avalanche photodiode solid-state PET detector technology, which addresses the functional incompatibility of MR and PET. With the Biograph mMR, patients can be scanned in as few as 30 minutes for a combined whole-body exam, compared to one hour or more for sequential MR and PET exams. Additionally, Biograph mMR has a footprint comparable to a standard, high-field MR scanner and can be sited in a typical MR room, eliminating renovation costs for facilities seeking to replace an existing MRI.
Earlier this year, Siemens Healthcare received the 2011 North American Frost & Sullivan Award for New Product Innovation for the Biograph mMR. The Growth Partnership Company presented the award to Siemens for demonstrating excellence in the following categories: innovative element of the product, leverage of leading-edge technologies, value-added features/benefits, increased customer return on investment (ROI), and customer acquisition/penetration potential.
The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 48,000 employees worldwide and operates around the world. In fiscal year 2010 (to September 30), the Sector posted revenue of 12.4 billion euros and profit of around 750 million euros. For further information please visit: www.siemens.com/healthcare.
|SOURCE Siemens Healthcare Sector|
Copyright©2010 PR Newswire.
All rights reserved